Literature DB >> 3075463

Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis.

G Husby1, R C Williams.   

Abstract

Tissue localization of tumor necrosis factor (TNF alpha) was examined in synovial tissues from 10 patients with active rheumatoid arthritis (RA) and three osteoarthritis controls using both monoclonal and polyclonal antibodies to TNF alpha and immunoperoxidase technique. No prominent staining for TNF alpha was noted in any of the osteoarthritis non-inflammatory synovial samples; however, six out of 10 RA synovial tissues displayed strongly positive tissue distribution of TNF alpha epitopes particularly within synovial lining cells, and interstitial monocyte/macrophage cells within inflammatory infiltrates. The amounts of TNF alpha visualized within synovial lining cells appeared to parallel the extent of inflammatory cell collections within the rheumatoid synovial tissues examined. Similar studies using renal biopsy tissues from seven patients with Systemic Lupus Erythematosus (SLE) nephritis (including diffuse proliferative nephritis, nephrotic syndrome, focal glomerulonephritis, and membranous nephritis) showed no tissue localization of TNF alpha. These findings emphasize that a potent lymphokine (TNF alpha), which may be important in the underlying inflammatory process, appears to be localized and perhaps produced by synovial lining cells within active RA synovial tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3075463     DOI: 10.1016/0896-8411(88)90006-6

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  33 in total

1.  Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis.

Authors:  B Heilig; M Wermann; H Gallati; M Brockhaus; B Berke; O Egen; A Pezzutto; W Hunstein
Journal:  Clin Investig       Date:  1992-01

Review 2.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

Review 3.  Hypoxia and inflammatory synovitis: observations and speculation.

Authors:  C R Stevens; R B Williams; A J Farrell; D R Blake
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

4.  Effect of auranofin on cytokine induced secretion of granule proteins from adherent human neutrophils in vitro.

Authors:  J Richter
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

Review 5.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 6.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  P E Lipsky; L S Davis; J J Cush; N Oppenheimer-Marks
Journal:  Springer Semin Immunopathol       Date:  1989

7.  Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis.

Authors:  J W Fuseler; E M Conner; J M Davis; R E Wolf; M B Grisham
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

8.  Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells.

Authors:  Chinh N Tran; Steven K Lundy; Peter T White; Judith L Endres; Christopher D Motyl; Raj Gupta; Cailin M Wilke; Eric A Shelden; Kevin C Chung; Andrew G Urquhart; David A Fox
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

9.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis.

Authors:  A E Koch; S L Kunkel; L A Harlow; B Johnson; H L Evanoff; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls.

Authors:  S Ruschen; W Stellberg; H Warnatz
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.